Sales of brain function enhancer ‘choline alfoscerate’ are on the rise in the prescription drug market. The drug recorded growth for 3 consecutive quarters despite controversy over its efficacy, reduced scope of reimbursement, and the restitution of insurance benefits. Also, with many CA products withdrawing from the market after giving up clinical re-evaluations, the market dominion has fluctuated.

According to the market research institution on the 25th, the outpatient prescriptions in Q3 recorded ₩127.3 billion. This was a 5.4% decrease YOY, however, also a 3-quarter consecutive rise from the ₩116.7 billion in Q4 last year. The cumulative prescription of choline alfoscerate products was &